| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 1g | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Cosalane targets CCR7, a chemokine receptor involved in immune cell migration, and inhibits CCR7 signaling in both humans and mice. It blocks the binding of CCR7 to its natural ligands, CCL19 and CCL21, with IC50 values of 0.207/2.66 μM (human) and 0.193/1.98 μM (mouse) for CCL19/CCL21, respectively. It also disrupts the interaction between gp120 and CD4, blocking HIV entry.
|
|---|---|
| ln Vitro |
Cosalane is a potent inhibitor of HIV replication with activity against a wide range of HIV-1 isolates, HIV-2, Rauscher murine leukemia virus, HSV-1, HSV-2, and human cytomegalovirus. It inhibits the binding of gp120 to CD4 cells and post-binding events leading to viral fusion. It blocks CCR7 signaling with IC50 values in the sub-micromolar to low-micromolar range.
|
| ln Vivo |
Cosalane has been studied in models of acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation. Its ability to block CCR7 signaling may modulate immune responses and reduce aGVHD. Its antiviral activity has been demonstrated in vitro against various viruses.
|
| Enzyme Assay |
In vitro enzyme or receptor binding assays for Cosalane measure its affinity for CCR7 and its ability to block ligand binding. The receptor is incubated with a radiolabeled ligand (CCL19 or CCL21) and varying concentrations of Cosalane, and displacement is measured. Its inhibition of HIV entry can be assessed using cell-cell fusion assays or pseudovirus entry assays.
|
| Cell Assay |
In vitro cellular assays for Cosalane involve treating HIV-infected cells with the compound and measuring viral replication. Its ability to inhibit gp120-CD4 binding can be assessed using cell-based assays where CD4-expressing cells are incubated with gp120 and the compound. Its effects on CCR7 signaling can be measured by assessing calcium mobilization or chemotaxis in response to CCL19 or CCL21.
|
| Animal Protocol |
In vivo animal models for Cosalane include models of acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation. In these models, mice are treated with Cosalane, and the severity of aGVHD is assessed. Its antiviral efficacy can be evaluated in animal models of HIV infection or other viral infections.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Cosalane are limited. As a small molecule, it is expected to be absorbed after oral administration and distributed to tissues. Its half-life and metabolism are not well-characterized. Its ability to cross the blood-brain barrier and its tissue distribution are subjects of ongoing research.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Cosalane is not extensively documented. As an HIV replication inhibitor and CCR7 antagonist, its safety in humans has not been fully established. Its potential for immunomodulation may lead to immune-related adverse events. Standard laboratory safety precautions should be followed when handling the compound.
|
| References |
Casimiro-Garcia A, De Clercq E, Pannecouque C, Witvrouw M, Loftus TL, Turpin JA, Buckheit RW Jr, Fanwick PE, Cushman M. Synthesis and anti-HIV activity of cosalane analogues incorporating two dichlorodisalicylmethane pharmacophore fragments. Bioorg Med Chem. 2001 Nov;9(11):2827-41. PubMed PMID: 11597463.
|
| Additional Infomation |
Cosalane is a potent HIV replication inhibitor and CCR7 antagonist with activity against a variety of HIV-1 strains, HIV-2, and other viruses. It inhibits gp120-CD4 binding and post-binding events. It blocks CCR7 signaling with IC50 values in the sub-micromolar range. It has been studied for its potential in treating HIV and modulating aGVHD.
|
| Molecular Formula |
C45H60CL2O6
|
|---|---|
| Molecular Weight |
767.869
|
| Exact Mass |
766.377
|
| CAS # |
154212-56-3
|
| Related CAS # |
154212-56-3;
|
| PubChem CID |
455040
|
| Appearance |
White to off-white solid powder
|
| Density |
1.191g/cm3
|
| Boiling Point |
797.4ºC at 760mmHg
|
| Flash Point |
436.1ºC
|
| Vapour Pressure |
7.99E-27mmHg at 25°C
|
| LogP |
12.75
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
53
|
| Complexity |
1280
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@@H](C4)CCC=C(C5=CC(=C(C(=C5)Cl)O)C(=O)O)C6=CC(=C(C(=C6)Cl)O)C(=O)O)C)C
|
| InChi Key |
VOJOOGPALCATLT-ZFQBPCNVSA-N
|
| InChi Code |
InChI=1S/C45H60Cl2O6/c1-25(2)8-6-9-26(3)35-14-15-36-32-13-12-30-20-27(16-18-44(30,4)37(32)17-19-45(35,36)5)10-7-11-31(28-21-33(42(50)51)40(48)38(46)23-28)29-22-34(43(52)53)41(49)39(47)24-29/h11,21-27,30,32,35-37,48-49H,6-10,12-20H2,1-5H3,(H,50,51)(H,52,53)/t26-,27+,30+,32+,35-,36+,37+,44+,45-/m1/s1
|
| Chemical Name |
Benzoic acid, 3,3'-(4-(3beta,5alpha)-cholestan-3-yl-1-butenylidene)bis(5-chloro-6-hydroxy-
|
| Synonyms |
Cosalane NSC 658586 NSC-658586
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3023 mL | 6.5115 mL | 13.0230 mL | |
| 5 mM | 0.2605 mL | 1.3023 mL | 2.6046 mL | |
| 10 mM | 0.1302 mL | 0.6512 mL | 1.3023 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA